Press Release
June 30, 2023

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million

The Life Sciences team advised Morphimmune on the intellectual property aspects of its definitive merger agreement with Immunome (Nasdaq: IMNM).

The companies also announced an oversubscribed private placement investment of $125 million with participation from Enavate Sciences, EcoR1 Capital, Redmile Group, Janus Henderson Investors, Avidity Partners, Woodline Partners LP, and other leading institutional investors.

Morphimmune is a biotechnology company focused on developing targeted oncology therapeutics.

Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care.

The Goodwin intellectual property team was led by Sabrina Poulos and Gregory Gutierrez.

For more details, read the press release and article in Fierce Biotech.